Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Ayumi Uchiyama, MD"'
Autor:
Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100508- (2023)
Introduction: Lorlatinib is an ALK tyrosine kinase inhibitor approved in Japan for the treatment of advanced ALK+ NSCLC. There has been little evidence about lorlatinib efficacy after first-line (1L) alectinib in clinical practice in Japan. Methods:
Externí odkaz:
https://doaj.org/article/bcbe60e4a4f34c35855ba34ee7b7698a